LOGIN  |  REGISTER
C4 Therapeutics

Neogen Announces Third-Quarter Earnings Release Date

March 20, 2025 | Last Trade: US$5.88 0.05 -0.84

LANSING, Mich., March 20, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) will issue its third-quarter earnings release before the opening of the market on Wednesday, April 9, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results.

The conference call can be accessed by dialing:
Toll-Free - North America: 1-800-549-8228
International: (+1) 646-564-2877
Conference ID: 63045

The live webcast can be accessed through Neogen's Investor Relations webpage, neogen.com/investor-relations, under the "Events & Presentations" subheading.

A replay of the conference call and webcast will be available shortly following the conclusion of the call and can be accessed by dialing:

Toll-Free - North America: 1-877-674-7070
International: (+1) 416-764-8692
Passcode: 63045 #

It will also be available on Neogen's Investor Relations website at neogen.com/investor-relations.

About Neogen

Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.  

Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page